ArticleFrontiers in medicine2025
Development of a predictive tool for long-term prognosis in clear cell adenocarcinoma of the cervix: a large population-based real-world study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell adenocarcinoma of the cervix (CCAC) is a rare malignancy without a well-established prognostic model. Our study aimed to develop and validate a nomogram to estimate overall survival in CCAC patients. Methods: We collected data on 630 CCAC patients from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2021). Missing clinicopathological data were imputed using the missForest package. The imputed dataset served as the training cohort, while the dataset with missing values removed acted as the validation cohort. The nomogram's performance was assessed through discriminative ability, calibration, C-index, AUC, and calibration plots. Clinical benefits were compared against the International Federation of Gynecology and Obstetrics (FIGO) staging using decision curve analysis (DCA), net reclassification index (NRI), and integrated discrimination improvement (IDI). Results: The nomogram, based on nine variables, demonstrated strong discriminative power, with C-index values of 0.82 for the training cohort and 0.81 for the validation cohort, and AUCs exceeding 0.80 in both sets. Calibration plots showed a strong agreement between the nomogram's predictions and actual outcomes in both cohorts. The NRI values for the training set were 0.21 for 3-year, 0.20 for 5-year, and 0.30 for 10-year overall survival (OS) predictions, and for the validation set were 0.34 for 3-year, 0.25 for 5-year, and 0.31 for 10-year OS predictions. The IDI results for the training set were 0.17 across 3-, 5-, and 10-year OS predictions, and for the validation set were 0.21 for 3-year, 0.17 for 5-year, and 0.15 for 10-year OS predictions. The nomogram significantly outperformed the FIGO criteria ( Conclusion: The nomogram, which integrates treatment data, was successfully developed and validated to assist clinicians in assessing the prognosis of CCAC patients. It demonstrated superior performance to FIGO criteria in predicting overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.